{
  "docId": "019de074-2557-77dc-997c-34813158de99",
  "docSlug": "5df8d2698ec92d4699700c9c99264cb6",
  "documentTitle": "Alkermes | Investor Presentation Deck | 28 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 28,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "other",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The slide uses PharmacoEEG heatmaps to visualize brain activity frequency over time.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2557-77dc-997c-34813158de99/17",
  "deckHref": "/decks/019de074-2557-77dc-997c-34813158de99",
  "deckJsonHref": "/decks/019de074-2557-77dc-997c-34813158de99.json",
  "deckAnchorHref": "/decks/019de074-2557-77dc-997c-34813158de99#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.8,
        "x": 0.1,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Cortical Arousal Rat PharmacoEEG",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9faf0b3-dca6-49b4-a251-230f753bb141",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "Selective orexin 2 receptor agonist demonstrated dose-dependent wake duration (shown by red gamma bands and dark blue theta and delta bands)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee608d59-36f8-4c48-b3e3-9e3de051f5b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.05,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "PharmacoEEG: Pharmaco-electroencephalography; Alkermes data on file",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f36d8ba-fae3-4c07-b6b8-d8231ae24202",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Selective Orexin 2 Receptor Agonist Promoted Prolonged Wakefulness in Preclinical In Vivo Studies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47ecf83a-6e2c-4ef2-858c-33e47e21034f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "6465cb11-c2d5-4a20-ab15-adc2f2874468",
      "evidence": "Selective Orexin 2 Receptor Agonist Promoted Prolonged Wakefulness in Preclinical In Vivo Studies with heatmap/chart",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 13,
      "beatId": "455311ba-8ac4-47bd-a45a-0bcdde58b22a",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The deck outlines clear priorities and a roadmap for growth.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 13,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "720f4a4f-461e-4591-8c2c-8988df913da8",
      "evidence": "The deck presents the clinical development plan and timeline.",
      "position": 1,
      "objective": "Why is now the right time to advance the orexin 2 receptor agonist?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}